Biolocity Portfolio Status September 2023



Category	Project or Company	Description	Bonch	Stage of Dev Broclinical	velopment	Markat
<u> </u>	Name	Our team will seek to translate a therapeutic enzyme to reverse	Bench	Preclinical	Clinical	warket
	Mageia Therapies	immunosuppression in solid tumors. PI: John Blazeck, PhD (GT)	•			
		A vaccine candidate consisting of a virus-like particle present on the				
	NanoCliq	Leishmania parasite, to prevent the onset of Leishmaniasis. PI: M.G. Finn, PhD (GT)	•			
		Safer and more effective next-generation 5-FU-based therapeutics. Pis:				
	Next-Gen 5-FU	Dennis Liotta, PhD (Emory), Eric Miller, PhD (Emory), John Petros, MD	•			
		(Emory), and Nicole Pribut, PhD (Emory)				
	CXCR4	Best-In-Class Orally Bioavailable CXCR4 Antagonists Heat Up Solid Tumors.				
	CXCR4	(Emory), and John Petros, MD (Emory)		•		
		A therapeutic strategy to overcome the pharmacological drawbacks of				
	Agrithera*	cannabidiol (CBD) for epilepsy using prodrugs that metabolize to CBD in the	•	•		
		body. PI: Dennis Liotta (Emory) Development of an LBH-1 agonist to target inflammation without the side				
	Allonix*	effects seen with global immunosuppression. PIs: Nathan Jui, PhD (Emory)	•	•		
		and Eric Ortlund, PhD (Emory)				
		An early-stage cell therapy company developing a mesothelin-specific				
	Athena (Ares	chimeric antigen receptor (CAR) T cell product for the treatment of	•	•		
	Immunotherapy)*	Paulos PhD (Emory)				
		RNA-based therapy for converting cardiomyocytes into a pacing phenotype				
	BioPace	to regulate heart rate. PIs: Hee Cheol Cho, PhD (Emory) and Phil	•	•		
		Santangelo, PhD (GT)				
Therapeutics	Cambium Oncology*	Small molecule VIP-receptor antagonist for immuno-oncology. PI: Ned	•	•		
		Gold nanoparticle coated with target-specific catalytic deoxyribozymes				
	Centizyme	therapeutic for severe asthma. PIs: Cherry Wongtrakool, MD (Emory) and	•	•		
		Khalid Salaita, PhD (Emory)				
	Marpé Therapeutics*	Isolated host defense peptides for the treatment of viruses, including	•	•		
	MetaClipse*	Tumor membrane vesicles for immuno-oncology treatment of triple				
		negative breast cancer. PI: Periasamy Selvaraj, PhD (Emory)	•	•		
	NephroDI*	Small molecule drug for Nephrogenic Diabetes Insipidus, a pediatric orphan	•			
		indication. PIs: Jeff Sands, MD (Emory) and Janet Klein, PhD (Emory)		•		
	Pyrefin*	Small molecules targeting the EP2 receptor to treat chronic inflammatory				
		diseases. PIs: Thota Ganesh, PhD (Emory) and Raymond Dingledine, PhD	•	•		
		(Emory)				
	SaGA for Cancer Drug	Utilizes a novel isolation assay for metastatic "leader" cells in solid tumors	•	•		
	Discovery					
	TPAM siRNA*	siRNA therapeutic to stop the progression, and potentially even regress,	•			
		atherosclerotic plaque formation. PI: Hanjoong Jo, PhD (Emory)				
	Urearetics	A novel mechanism to treat uremic pericarditis and pericardial effusions in				
		chronic kidney disease patients by inhibiting urea transport. PI: Jeff Sands MD (Emony)	•	•		
		SIRPAION engineered macrophage immunotherapy for treatment of solid				
	SIRPant*	tumors. PIs: Yuan Liu PhD (GSU) and Ned Waller, MD, PhD (Emory)	•	•	•	
Diagnostics	Heteroresistance	Approach to determine antibiotic susceptibility in <2 hrs of blood culture.				
	AST	PIs: David Weiss, PhD (Emory) & Peter Yunker, PhD (GT)	•	•	•	
	Sanguina*	Quick, disposable, handheld biochemical device that provides a				
		quantitative evaluation of anemia in less than two minutes. PI: Wilbur	•	•	•	•
		OZ-Link's mission is to develop a generalizable delivery platform that				
	OZ-Link	enables the extended and precise controlled release of protein	•			
		therapeutics. PI: M.G. Finn (GT)				
Drug Delivery	Twice Therapeutics	Targeted gene therapy delivery to many cell types without the need to				
		(Emory)	•			
	CorAmi*	A drug delivery platform for localized delivery of therapeutic-seeded				
		hydrogels to the pericardial space PIs: Rebecca Levit, MD (Emory) &	•	•		
		Anores Garcia, PND (GT) Site-specific delivery of dexamethasone to the surgical site to avoid side				
	DexaPatch	effects of systemic steroid delivery. PIs: Adam Klein, MD (Emory), Daniel	•	•		
		Refai, MD (Emory), & Andrés García, PhD (GT)				
	ProLymph Nano	Drug delivery technology unlocks new market opportunities by targeting the lymphatic system. PI: Susan Thomas. PhD (GT)	•	•		



Catagory	Project or Company Name	Description	Stage of Development			
Category			Bench	Preclinical	Clinical	Market
Cell Mfg	Andson Biotech*	A platform technology that provides accurate and low-cost quality monitoring for cell therapy bioreactors. PIs: Andrei Fedorov, PhD (GT) & Edwin Horwitz, MD (Emory)	•			
	CellFE*	Cell processing and treatment technologies that will enable better manufacturing and functionalization of cell therapies. PI: Todd Sulchek, PhD (GT)	•	•		
Software & Digital Health	Bystro	A search engine for your life-sciences data. PI: Thomas Wingo, MD (Emory)	•			
	Sanicka*	A clinical decision support tool to aid treatment selection and optimization for leukemia patients. PIs: Nicki Panoskaltsis, MD (Emory) & Sakis Mantalaris, PhD (GT)	•			
	AngioCloud*	Cloud-based software with the selection and deployment of neurointerventional devices. PIs: Frank Tong, MD (Emory) & Alessandro Veneziani, PhD (Emory)	•	•	•	
	Covanos*	Software tool for automated quantification of Left Ventricle Fractional Flow Reserve. PIs: Habib Samady, MD (Emory) & Don Giddens, PhD (GT)	•	•	•	
	Emtherapro	Diagnostic platform for pre-clinical detection and quantification of functional neurodegenerative biomarkers. PIs: Allan Levy, MD (Emory) & Nick Seyfried, PhD (Emory)	•	•	•	
	Repredix	Mobile technology for detection of CHF decompensation. PIs: Gari Clifford, PhD (Emory) & Amit Shah, MD (Emory)	•	•	•	
	Codoxo*	Provides intelligent claims analysis to help identify, address, and mitigate payment of fraudulent healthcare billing. PI: Mustaque Ahamad, PhD (GT)	•	•	•	•
Devices	Cellcue Bio	3D microfluidic platform for cell therapies with improved prediction of clinical outcomes. PI: Andrés García, PhD (GT) & Wilbur Lam, MD, PhD (Emory)	•			
	Fecal Matter Processor*	Device for improved and simplified processing of fecal matter for fecal transplantation therapy. PIs: Bob Taylor, MD (Emory) & Colleen Kraft, MD (Emory)	•			
	Focused Cryo*	Cryoablation system with real-time temp. sensing and directionality to suggest optimal probe insertion path. PIs: Yogi Patel, PhD (Emory) & David Prologo, MD, FSIR (Emory)	•			
	Lybbie*	Fully wearable breast pump that allows for hands-free pumping and improved mobility for breast-feeding mothers. PI: Andrea Joyner, MD (Emory)	•			
	Piggy-Back Heart	A self-powered heart pump that harvests native motion of the right ventricle to enhance blood flow in Fontan circulation for patients with hypoplastic left or right heart syndrome. PI: Murali Padala, PhD (Emory)	•			
	Robotic Guidewire	Robotically steerable guidewire for interventional radiology procedures. PIs: Zachary Bercu, MD (Emory) & Jaydev Desai, PhD (GT)	•			
	Sleep Monitoring Biopatch	A soft, wearable biosensor patch and accompanying software to enable athome sleep testing. PI: Woon-Hong Yeo, PhD (GT)	•			
	Nyra*	A transcatheter implant that seeks to "plug" the fluid path, which is seen in patients with mitral regurgitation. PI: Murali Padala, PhD (Emory)	•	•		
	Periurethral Bulking*	Device for standardizing bulking material delivery for the treatment of urinary incontinence. PI: Nail Galloway, MD (Emory)	•	•		
	TriLEN	A modified leaflet implant that can be sized for pediatric patients to repair tricuspid or atrioventricular valve regurgitation. PI: Murali Padala, PhD (Emory)	•	•		
	CameRad*	Device to reduce mismatch of radiology imaging and patient identities. PIs: Pamela Bhatti, PhD (GT) & Srini Tridandapani, MD, PhD, MBA (Emory)	•	•	•	
	BRIJJIT*	Wound closure technology to reduce formation of scars. PI: Monte Eaves, MD (Emory)	•	•	•	•
	Dr. NozeBest*	Battery-powered suction device designed to clear nasal congestion in babies and children. PI: Steven Goudy, MD (Emory)	•	•	•	•
	Jackson Medical*	Device to reduce the risk of endoscope-related procedure drape fires. PI: James Rains, PE (GT)	•	•	•	•

Note: * denotes a company has been formed